TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28568169
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 0.05 mg/kg IM q24h
Study: 28568169
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (FLUT) 3,000 μg q12h
Study: 19389262
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and placebo medicine
Study: 19389262
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture and Flunarizine (10 mg once per night for the first 2 weeks, then 5 mg once per night for the next 2 weeks)
Study: 18181333
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine trial with education and risk reduction counseling every six months
Study: 9674806
Drug: Nimodipine 60
Normalized name: nimodipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 60 mg p.o., five times daily
Study: 9674806
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg p.o., three times daily
Study: 7985514
Drug: Acetaminophen in
Normalized name: acetaminophen Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen in Tibetan
Study: 7985514
Drug: Acetaminophen in
Normalized name: acetaminophen Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen in Han
Study: 2692576
Drug: Oral immunostimulant
Normalized name: IMMUNOSTIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunostimulant
Study: 31415908
Drug: GLP-1 RA
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLP-1 RA exenatide (acute administration)
Study: 31415908
Drug: GLP-1 RA
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLP-1 RA liraglutide (titrated up to 1.8 mg daily for 12 weeks)
Study: 26354385
Drug: Long-term domiciliary
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term domiciliary oxygen therapy (LTDOT) for more than 15 hours every day with continuous low flow (1-2 L/min) for 3 years
Study: 26354385
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no additional oxygen therapy)
Study: 23333143
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day for 9 days
Study: 21529841
Drug: NFKB1 (g.-24519delATTG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFKB1 (g.-24519delATTG) variant
Study: 21529841
Drug: NFKBIA (g.-1004A>G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFKBIA (g.-1004A>G) variant
Study: 17132302
Drug: Placebo (vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vaccine diluent)
Study: 22201658
Drug: Telephone calls
Normalized name: Mosco Corn & Callus Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone calls from a peer counselor once weekly for five weeks beginning six weeks postsurgery
Study: 24521107
Drug: Mebendazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (500 mg)
Study: 12883542
Drug: Twice-weekly supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly supervised exercise training
Study: 3753363
Drug: Spironolactone (S)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone (S) 25 mg orally, four times per day
Study: 27609408
Drug: benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: benralizumab 30 mg Q4W
Study: 27609408
Drug: benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: benralizumab 30 mg Q8W
Study: 12649124
Drug: SCH55700 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH55700 1.0 mg/kg
Study: 12649124
Drug: SCH55700 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH55700 0.3 mg/kg
Study: 11194275
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg delayed release for 7 to 9 weeks)
Study: 18595418
Drug: Bupropion plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion plus nicotine patch
Study: 30561264
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (simvastatin + ezetimibe)
Study: 24408305
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg ISU303
Study: 24408305
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg ISU303
Study: 22115011
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ezetimibe/simvastatin 10/20mg (C)
Study: 16504368
Drug: Tibolone (Livial)
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (Livial) 2.5 mg/day + Alendronate sodium (Fosamax) 10 mg/day
Study: 16504368
Drug: Alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate sodium (Fosamax) 10 mg/day
Study: 9354202
Drug: 1-week triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week triple therapy of omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tetracycline 500 mg b.d. (OCT)
Study: 9354202
Drug: 2-week dual
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week dual therapy of omeprazole 20 mg b.d. and amoxycillin 1 g b.d. (OA)
Study: 9354202
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with OCT therapy after OA failure
Study: 9354202
Drug: Overall success
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall success rate for triple and dual therapy sequence
Study: 9354202
Drug: Overall success
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall success rate for dual followed by triple therapy
Study: 8250615
Drug: Colchicine (0.6‐1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.6‐1.8 mg/day)
Study: 3457171
Drug: 1.23% acidulated
Normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% acidulated phosphate fluoride gel
Study: 11253275
Drug: 0.05% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% sodium fluoride solution
Study: 3457171
Drug: 0.2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% sodium fluoride solution
Study: 30390943
Drug: Intraperitoneal carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal carboplatin (AUC 6) every 3 weeks with intravenous paclitaxel weekly at 80 mg/m2
Study: 30390943
Drug: Intraperitoneal carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal carboplatin and intravenous paclitaxel
Study: 26956031
Drug: Assigned treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assigned treatment
Study: 24127851
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics with single-dose i.v. cefazolin (1 g)
Study: 24127851
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics with single-dose i.v. ceftriaxone (1 g)
Study: 24127851
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics with oral levofloxacin (500 mg)
Study: 24127851
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (all types)
Study: 22736124
Drug: Non-antibiotics restriction
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antibiotics restriction group
Study: 22736124
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation group
Study: 22736124
Drug: Antibiotic restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic restriction group
Study: 18377127
Drug: MET plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET plus cognitive-behavioral therapy (CBT)
Study: 16898079
Drug: r-hIL-18 BP
Normalized name: (R)-p-mentha-1,8-diene
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hIL-18 BP (20, 70, 210 or 350 mg, sc)
Study: 16898079
Drug: r-hIL-18 BP
Normalized name: (R)-p-mentha-1,8-diene
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hIL-18 BP (35 or 175 mg, sc, 6 injections, 48 h apart)
Study: 16898079
Drug: r-hIL-18 BP
Normalized name: (R)-p-mentha-1,8-diene
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hIL-18 BP (20, 160 or 320 mg, sc tiw)
Study: 16898079
Drug: r-hIL-18 BP
Normalized name: (R)-p-mentha-1,8-diene
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hIL-18 BP (20, 80, 160 mg, sc tiw)
Study: 14593351
Drug: Bisoprolol (1.25‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (1.25‐10 mg/day)
Study: 1335442
Drug: L-carnitine during
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine during ECC
Study: 1335442
Drug: L-carnitine before
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine before and during ECC
Study: 25335251
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy group (electroacupuncture at qi streets acupoints combined with spinal regulation method)
Study: 31930890
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy group
Study: 25335251
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy group and medication group
Study: 23910646
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg/day with peginterferon alfa plus ribavirin
Study: 12788962
Drug: Long-acting β2-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β2-agonists (salmeterol or formoterol) used as second-line treatment for 1 week or more
Study: 11105182
Drug: Antiemetic pharmacotherapy
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiemetic pharmacotherapy alone
Study: 8731623
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment and education/advice
Study: 1574950
Drug: Simvastatin 10‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10‐40 mg/day
Study: 26401946
Drug: Serum lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum lutein (L) concentrations
Study: 23273405
Drug: Fluticasone/formoterol 250/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol 250/10 μg b.i.d.
Study: 19278300
Drug: 375 μg
Normalized name: penicillin G 375 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 μg interferon-β-1b
Study: 19278300
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg interferon-β-1b
Study: 11691573
Drug: Isepamicin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin at 7.5 mg/kg i.v. q 12 h
Study: 11691573
Drug: Amikacin at
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin at 7.5 mg/kg i.v. q 12 h
Study: 8131769
Drug: Captopril, 25
Normalized name: Captopril, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 25 mg three times daily
Study: 24711481
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who experienced syncope post pacemaker implant
Study: 23078636
Drug: Temptation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temptation to drink (self-reported measure during the fourth session of treatment)
Study: 14599997
Drug: Tiredness in
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiredness in daily activities (measured by questionnaire surveys)
Study: 11072443
Drug: Carbidopa/levodopa (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/levodopa (25 mg carbidopa and 100 mg levodopa, one tablet TID for 1 week, 1 1/2 tablets TID for 1 week, then two tablets TID for 6 weeks)
Study: 8773860
Drug: 1 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg-1 ketorolac i.v.
Study: 8773860
Drug: 1.5 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg.kg-1 codeine im
Study: 1335644
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine lot 1
Study: 1335644
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine lot 2
Study: 1335644
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine lot 3
Study: 1335644
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine lots 1, 2, and 3
Study: 6138083
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg triazolam
Study: 6138083
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg alpha-hydroxy midazolam
Study: 6138083
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alpha-hydroxy triazolam
Study: 6138083
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 4-hydroxy triazolam
Study: 31209630
Drug: Scrambler Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrambler Therapy
Study: 11279797
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor cell vaccines (10 million irradiated tumor cells with various adjuvants, weekly x3 and then monthly x5)
Study: 11279797
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor cell vaccines
Study: 9644824
Drug: Concurrent articulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent articulation during the serial report task
Study: 9644824
Drug: Concurrent tapping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent tapping during the serial report task
Study: 3062604
Drug: Triamterene-containing preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene-containing preparation
Study: 11684372
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 microg/die for 12 cycles
Study: 11684372
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches for 12 cycles
Study: 11049919
Drug: Low-flow sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-flow sevoflurane anesthesia (1 L/min)
Study: 27413741
Drug: High-flow sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-flow sevoflurane anesthesia (4 L/min)
Study: 23268736
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral vitamin D3 dose (70,000 IU)
Study: 19887137
Drug: ACWY-TT conjugate
Normalized name: Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACWY-TT conjugate vaccine
Study: 16045141
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous ketamine (0.15 mg kg(‐1))
Study: 1902253
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous ketamine
Study: 11819728
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (Group A)
Study: 12394893
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Group B)
Study: 10363198
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (interferon alpha + oral ribavirin)
Study: 10363198
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (interferon alpha + oral ribavirin + oral amantadine)
Study: 8881849
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen patch releasing 50 micrograms oestradiol 24 h-1
Study: 26401247
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron therapy
Study: 26648450
Drug: Topical coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical coenzyme Q10-containing formulas
Study: 19715381
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal soluble film (FBSF) pH 6
Study: 19715381
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal soluble film (FBSF) pH 7.25
Study: 19715381
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal soluble film (FBSF) pH 8.5
Study: 17890356
Drug: Fixed contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed contrast material dose (120 mL of iohexol 300) at an injection rate of 4.0 mL/sec (Protocol 1)
Study: 17890356
Drug: Dose tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose tailored to patient's body weight (2.0 mL/kg) injected over 30 seconds (Protocol 2)
Study: 14999221
Drug: PT-141 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT-141 (4 mg)
Study: 14999221
Drug: PT-141 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT-141 (6 mg)
Study: 14999221
Drug: PT-141 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT-141 (0.3 to 10 mg)
Study: 11146577
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with transdermal estrogen with or without progestogen
Study: 11146577
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen with and without progestogen
Study: 9832298
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (2 mg x kg(‐1)) during the acute phase
Study: 9832298
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (2 mg x kg(‐1)) during the acute phase
Study: 9832298
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (2 mg x kg(‐1)) after remission
Study: 8077885
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 1.2 mg day-1 to 2.0 mg day-1 (n = 9)
Study: 2812839
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of lactulose
Study: 2812839
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of lactulose (placebo)
Study: 12443672
Drug: Oral killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral killed cholera vaccine
Study: 779998
Drug: Oral live
Normalized name: polio vaccine, oral live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral live cholera vaccine
Study: 779998
Drug: Parenteral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral cholera vaccine
Study: 30543266
Drug: Ultrasound-guided hypertonic
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided hypertonic dextrose (20%) injection
Study: 30543266
Drug: 5% normal
Normalized name: dextrose 5%-0.225% normal saline (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% normal saline injection
Study: 28454576
Drug: Permethrin-fipronil combination
Normalized name: fipronil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin-fipronil combination (Effitix®) - treated three times every 4 weeks with a spot-on containing 54.5% permethrin and 6.1% fipronil.
Study: 28454576
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (Control group B).
Study: 21707928
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once a day for 12 weeks
Study: 16961291
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a combination of 10% glucose, Vitamin C, and Inosine
Study: 9412897
Drug: Calcium salts
Normalized name: lonazolac calcium salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium salts administration after CPB
Study: 12356634
Drug: Calcium administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium administration
Study: 3108105
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Sorbinil daily for 1 year
Study: 31907074
Drug: TANDEM intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: TANDEM intervention (tailored cognitive behavioural approach) delivered weekly for 6-8 weeks by trained respiratory healthcare professionals
Study: 30031660
Drug: DXA-derived visceral
Approvals — FDA: no, EMA: no, PMDA: no
Description: DXA-derived visceral adipose tissue measures (VAT, VAT/Total fat, visceral-to-subcutaneous fat)